Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Cocaine-Related Disorders · Cocaine Dependence · DRUG

BRIGHT MINDS BIOSCIENCES

BRIGHT MINDS BIOSCIENCES INC.

BRIGHT MINDS BIOSCIENCES clinical programs — 1063 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
19 Vestry St, New York, NY 10013, US HQ
12 Employees
Public company Type
DRUG · NYSE Ticker
Company details
Status
Public
HQ
19 Vestry St, New York, NY 10013, US
Employees
12
Programs
1063
Drugs
444
Patents
57
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Clinical Programs

BRIGHT MINDS BIOSCIENCES projects

1,063 ClinicalTrials.gov programs sponsored by BRIGHT MINDS BIOSCIENCES.

BRIGHT MINDS BIOSCIENCES has 1,063 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

1,063 programs

Clinical programs

Page 13 of 23

  1. Behavior Therapy-RISE

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid-Related Disorders

    phase 1 other completed

    1 trial

  2. CBD Day 1

    BRIGHT MINDS BIOSCIENCES INC.

    Addiction

    phase 1 small molecule completed

    1 trial

  3. CDD-2101

    BRIGHT MINDS BIOSCIENCES INC.

    Constipation - Functional

    phase 1 small molecule completed

    1 trial

  4. CI-581a

    BRIGHT MINDS BIOSCIENCES INC.

    Cannabis Dependence

    phase 1 small molecule completed

    1 trial

  5. CS-1103

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Use Disorders

    phase 1 small molecule completed

    1 trial

  6. CVL-354

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid Use Disorder

    phase 1 small molecule completed

    1 trial

  7. CVL-354

    BRIGHT MINDS BIOSCIENCES INC.

    Healthy Participants

    phase 1 small molecule completed

    1 trial

  8. Cannabidiol, Medium Dose

    BRIGHT MINDS BIOSCIENCES INC.

    Cannabis

    phase 1 small molecule active

    1 trial

  9. Cannabis

    BRIGHT MINDS BIOSCIENCES INC.

    Cannabis Intoxication

    phase 1 small molecule active

    2 trials

  10. Cannabis

    BRIGHT MINDS BIOSCIENCES INC.

    Pain

    phase 1 small molecule active

    2 trials

  11. Cannabis Cigarette

    BRIGHT MINDS BIOSCIENCES INC.

    Cannabis Use

    phase 1 small molecule completed

    1 trial

  12. Cannabis sativa Extract

    BRIGHT MINDS BIOSCIENCES INC.

    Cannabis Dependence

    phase 1 small molecule active

    1 trial

  13. Carbon Monoxide inhalation

    BRIGHT MINDS BIOSCIENCES INC.

    Smoking

    phase 1 small molecule terminated

    1 trial

  14. Cigarette

    BRIGHT MINDS BIOSCIENCES INC.

    Cigarette Smoker

    phase 1 small molecule completed

    1 trial

  15. Clarithromycin

    BRIGHT MINDS BIOSCIENCES INC.

    Drug-induced QT Prolongation

    phase 1 small molecule completed

    1 trial

  16. Clavulanic Acid

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Dependence, in Remission

    phase 1 small molecule completed

    1 trial

  17. Clavulanic acid

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Dependence

    phase 1 small molecule completed

    1 trial

  18. Cocaine

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Abuse

    phase 1 small molecule completed

    1 trial

  19. Cocaine

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Use Disorder

    phase 1 small molecule completed

    3 trials

  20. Cocaine (IV)

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-Related Disorders

    phase 1 small molecule active

    1 trial

  21. Cocaine Self-adminstration

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Dependence

    phase 1 small molecule completed

    1 trial

  22. Cocaine hydrochloride

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Induced Sympathoexciation and Vasoconstriction

    phase 1 small molecule terminated

    1 trial

  23. Cognitive-Behavioral Therapy

    BRIGHT MINDS BIOSCIENCES INC.

    Cannabis Dependence

    phase 1 other completed

    1 trial

  24. Cohort 1 - TMP-301

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Use Disorder

    phase 1 small molecule completed

    1 trial

  25. Cycloserine

    BRIGHT MINDS BIOSCIENCES INC.

    Nicotine Addiction

    phase 1 small molecule completed

    1 trial

  26. Cypep-1

    BRIGHT MINDS BIOSCIENCES INC.

    Cutaneous Warts

    phase 1 small molecule completed

    1 trial

  27. DF-003

    BRIGHT MINDS BIOSCIENCES INC.

    ROSAH

    phase 1 small molecule active

    1 trial

  28. Dabigatran

    BRIGHT MINDS BIOSCIENCES INC.

    Mild Cognitive Impairment

    phase 1 small molecule terminated

    1 trial

  29. Delta-9-THC Low Dose

    BRIGHT MINDS BIOSCIENCES INC.

    Age-related Cognitive Decline

    phase 1 small molecule active

    1 trial

  30. Dihydrexidine

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-Related Disorders

    phase 1 small molecule active

    1 trial

  31. Disulfiram

    BRIGHT MINDS BIOSCIENCES INC.

    HIV Infections

    phase 1 small molecule completed

    1 trial

  32. Divalproex Sodium Extended-release 250mg

    BRIGHT MINDS BIOSCIENCES INC.

    Epilepsy

    phase 1 small molecule active

    1 trial

  33. Dociparstat sodium

    BRIGHT MINDS BIOSCIENCES INC.

    Acute Myeloid Leukemia

    phase 1 small molecule completed

    1 trial

  34. Dofetilide

    BRIGHT MINDS BIOSCIENCES INC.

    Drug-induced QT Prolongation

    phase 1 small molecule completed

    1 trial

  35. Dronabinol

    BRIGHT MINDS BIOSCIENCES INC.

    Bipolar Disorder

    phase 1 small molecule terminated

    1 trial

  36. Dronabinol

    BRIGHT MINDS BIOSCIENCES INC.

    Schizophrenia

    phase 1 small molecule completed

    1 trial

  37. Dronabinol Capsules

    BRIGHT MINDS BIOSCIENCES INC.

    HIV

    phase 1 small molecule active

    1 trial

  38. Drug A (Blinded Drug)

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid Use Disorder

    phase 1 small molecule on hold

    1 trial

  39. EBC-129

    BRIGHT MINDS BIOSCIENCES INC.

    Advanced Solid Tumours

    phase 1 small molecule active

    1 trial

  40. ECHO (Empowering Our Community & Health Outcomes)

    BRIGHT MINDS BIOSCIENCES INC.

    Smoking Cessation

    phase 1 other terminated

    1 trial

  41. ECIG liquid vehicles

    BRIGHT MINDS BIOSCIENCES INC.

    Nicotine Exposure

    phase 1 other completed

    1 trial

  42. ENA-001

    BRIGHT MINDS BIOSCIENCES INC.

    Respiratory Depression

    phase 1 small molecule active

    1 trial

  43. ETC-159

    BRIGHT MINDS BIOSCIENCES INC.

    With MSS/pMMR Advanced, Platinum-resistant Ovarian Cancer

    phase 1 small molecule active

    1 trial

  44. ETC-1907206

    BRIGHT MINDS BIOSCIENCES INC.

    Ph+ Acute Lymphoblastic Leukemia (Ph+ALL)

    phase 1 small molecule terminated

    1 trial

  45. ETC-1922159

    BRIGHT MINDS BIOSCIENCES INC.

    Solid Tumors

    phase 1 small molecule active

    1 trial

  46. Empagliflozin 10 MG Oral Tablet [Jardiance]

    BRIGHT MINDS BIOSCIENCES INC.

    Diabetes Mellitus

    phase 1 small molecule completed

    1 trial

  47. Epidiolex

    BRIGHT MINDS BIOSCIENCES INC.

    CBD

    phase 1 small molecule active

    1 trial

  48. Evaluate the effects of Environmental Enrichment (EE) on alcohol consumption

    BRIGHT MINDS BIOSCIENCES INC.

    Alcohol Use Disorder

    phase 1 other active

    1 trial

Frequently asked questions

How many clinical projects does BRIGHT MINDS BIOSCIENCES have?

1,063 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.